NCT03407976 - Apatinib With Pembrolizumab in Previously Treated Advanced Malignancies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 19, 2018

Primary Completion Date

August 19, 2019

Study Completion Date

July 2, 2020

Conditions

Advanced MalignanciesUrothelial CarcinomaMSI-H or dMMR Solid TumorsGastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Interventions

DRUG

Apatinib

Apatinib oral daily at starting dose 1, Dose Level 2 or Dose Level 3 in phase I, and then whichever is the maximum tolerated dosage will be used for all Phase II patients.

DRUG

Pembrolizumab

200 mg Q3 weeks IV

Trial Locations (1)

84112

Huntsman Cancer Institute, Salt Lake City